TY - JOUR
T1 - Treatment of basal cell carcinoma with curettage alone
AU - Barlow, James O.
AU - Zalla, Mark J.
AU - Kyle, Amber
AU - DiCaudo, David J.
AU - Lim, Katherine K.
AU - Yiannias, James A.
PY - 2006/6/1
Y1 - 2006/6/1
N2 - Background: Although curettage and electrodesiccation (C&E) is widely used to treat basal cell carcinoma, whether electrodesiccation improves outcome is unknown. Objective: We sought to compare cure rates of curettage alone with those of C&E. Methods: We conducted a retrospective records review of patients treated with curettage alone at 5-year follow-up or longer that extracted data about tumor location, size, histologic subtype, biopsy specimen margin involvement, and recurrence, as well as data about the medical history of patients treated in a dermatology clinic in a tertiary-care academic medical institution. Results: Biopsy-proven tumors (302) amenable to treatment with C&E and treated by a single investigator with curettage alone had a 5-year cure rate of 96.03%, with minimal complications (hypopigmentation, scarring). Tumors involving more than 50% of the deep edge of the shave biopsy specimen had an increased risk of recurrence. Limitations: This is a retrospective study based on historic controls. Conclusion: For nonaggressive basal cell carcinoma, curettage alone has a cure rate similar to the published rates for C&E.
AB - Background: Although curettage and electrodesiccation (C&E) is widely used to treat basal cell carcinoma, whether electrodesiccation improves outcome is unknown. Objective: We sought to compare cure rates of curettage alone with those of C&E. Methods: We conducted a retrospective records review of patients treated with curettage alone at 5-year follow-up or longer that extracted data about tumor location, size, histologic subtype, biopsy specimen margin involvement, and recurrence, as well as data about the medical history of patients treated in a dermatology clinic in a tertiary-care academic medical institution. Results: Biopsy-proven tumors (302) amenable to treatment with C&E and treated by a single investigator with curettage alone had a 5-year cure rate of 96.03%, with minimal complications (hypopigmentation, scarring). Tumors involving more than 50% of the deep edge of the shave biopsy specimen had an increased risk of recurrence. Limitations: This is a retrospective study based on historic controls. Conclusion: For nonaggressive basal cell carcinoma, curettage alone has a cure rate similar to the published rates for C&E.
UR - http://www.scopus.com/inward/record.url?scp=33646519031&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33646519031&partnerID=8YFLogxK
U2 - 10.1016/j.jaad.2006.01.041
DO - 10.1016/j.jaad.2006.01.041
M3 - Article
C2 - 16713459
AN - SCOPUS:33646519031
SN - 0190-9622
VL - 54
SP - 1039
EP - 1045
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
IS - 6
ER -